yes! remember though the evil of just one bubble in the gel...how many times I had to recast those things

Thank you to our three researchers, Paul Foucambert, Szarina Ko and Thomas Vallet, for doing the heavy lifting in developing the vaccine candidates to test, and to the rest of the lab for rowing the boat along with them to get this project across the finish line. (3/3)

As a PhD student at, I was among the first to develop saRNA vaccines in the 1990s. Now, in Singapore, my lab will use the expertise we've built over the last 30 years to bring this technology to make safer, better and longer lasting vaccines that need fewer doses.
(2/3)

It's beautifully done, tells a whole proof of principle story, perfect for your journal club too!

download it here at Nature Biomedical Engineering:
rdcu.be/eH4le

BUT now, a million years later, my lab is revisiting all this stuff, saRNA vaccines, bacterial delivery systems, oncolytic therapies, with a modern updated touch.

READ this very cool paper by SINGER et al, one of my favourites for 2025 for sure!

We packaged all this up in a patent, but never published...because in the meantime, all that work on ribavirin resistance & polymerase fidelity side project took my career in a different direction!

to see the Salmonella stuff...it's buried in our patent:

patents.google.com/patent/US739...

The enzyme produced by asd gene (Aspartate-semialdehyde dehydrogenase) is essential for diaminopimelic acid (DAP) synthesis.

The Asd gene knockout meant that we could produce Salmonella in broth supplemented DAP, while in the host cell, the bacteria falls apart - missing its peptidoglycan wall.